# Unraveling the Underlying Molecular Mechanism of ‘Silent Hypoxia’ in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway

Christian Albert Devaux, Jean-Christophe Lagier

► To cite this version:

Christian Albert Devaux, Jean-Christophe Lagier. Unraveling the Underlying Molecular Mechanism of ‘Silent Hypoxia’ in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. Journal of Clinical Medicine, 2023, 12 (6), pp.2445. 10.3390/jcm12062445. [https://doi.org/10.3390/jcm12062445]

HAL Id: hal-04115601

https://amu.hal.science/hal-04115601

Submitted on 23 Jun 2023

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons Attribution 4.0 International License
<figure><img src="image_2.png" /></figure>

Review

# Unraveling the Underlying Molecular Mechanism of ‘Silent Hypoxia’ in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway

Christian Albert Devaux<sup>1,2,3,*</sup> and Jean-Christophe Lagier<sup>1,2</sup>

**Abstract:** A few days after being infected with SARS-CoV-2, a fraction of people remain asymptomatic but suffer from a decrease in arterial oxygen saturation in the absence of apparent dyspnea. In light of our clinical investigation on the modulation of molecules belonging to the renin angiotensin system (RAS) in COVID-19 patients, we propose a model that explains ‘silent hypoxia’. The RAS imbalance caused by SARS-CoV-2 results in an accumulation of angiotensin 2 (Ang II), which activates the angiotensin 2 type 1 receptor (AT1R) and triggers a harmful cascade of intracellular signals leading to the nuclear translocation of the hypoxia-inducible factor (HIF)-1α. HIF-1α transactivates many genes including the angiotensin-converting enzyme 1 (ACE1), while at the same time, ACE2 is downregulated. A growing number of cells is maintained in a hypoxic condition that is self-sustained by the presence of the virus and the ACE1/ACE2 ratio imbalance. This is associated with a progressive worsening of the patient’s biological parameters including decreased oxygen saturation, without further clinical manifestations. When too many cells activate the Ang II-AT1R-HIF-1α axis, there is a ‘hypoxic spillover’, which marks the tipping point between ‘silent’ and symptomatic hypoxia in the patient. Immediate ventilation is required to prevent the ‘hypoxic spillover’.

**Keywords:** COVID-19; silent hypoxia; angiotensin II; ACE2; renin-angiotensin system; AT1R; hypoxia-inducible factors; HIF-1; hypoxic spillover

## 1. Introduction

Severe acute respiratory syndrome cases were observed in Wuhan (China) in December 2019. This new disease (later named coronavirus disease 2019 or COVID-19) was characterized by acute respiratory distress (ARDS), cytokine storm, and thrombotic events leading to multiple organ dysfunction syndrome (MODS) and a risk of death. Shortly after the recognition of COVID-19, a new Sarbecovirus, the severe acute respiratory syndrome-related coronavirus 2 or SARS-CoV-2, was identified as the etiological agent of the disease [1,2]. Of the 670 million people who have been infected with SARS-CoV-2 since the beginning of the pandemic, a small fraction of those patients have experienced a severe form of the disease, and COVID-19 has been responsible for more than 6.8 million deaths (https://coronavirus.jhu.edu/map.html; accessed on 20 February 2023). Very quickly, angiotensin I-converting enzyme 2 (ACE2), a key modulator of the renin-angiotensin system (RAS)—also known as the renin-angiotensin-aldosterone system (RAAS)—was demonstrated to be the viral entry receptor for SARS-CoV-2 [3,4]. SARS-CoV-2 gains entry into alveolar type II epithelial lung cells [5,6], as well as many other cell types expressing a transmembrane ACE2, by way of its envelope spike (S) glycoprotein, which comprises S1 and S2 subunits. After attachment to ACE2 and S glycoprotein cleavage by serine protease

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Devaux, C.A.; Lagier, J.-C. Unraveling the Underlying Molecular Mechanism of ‘Silent Hypoxia’ in COVID-19 Patients Suggests a Central Role for Angiotensin II Modulation of the AT1R-Hypoxia-Inducible Factor Signaling Pathway. *J. Clin. Med.* **2023**, *12*, 2445. https://doi.org/10.3390/jcm12062445

Academic Editor: Vito Racanelli

Received: 22 February 2023

Revised: 17 March 2023

Accepted: 20 March 2023

Published: 22 March 2023

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

<footnote n="1">¹ Institut de Recherche pour le Développement, Assistance Publique Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infection Laboratory, Aix-Marseille University, 13000 Marseille, France</footnote>

<footnote n="2">² Institut Hospitalo-Universitaire—Méditerranée Infection, 13000 Marseille, France</footnote>

<footnote n="3">³ Centre National de la Recherche Scientifique, 13000 Marseille, France</footnote>

<footnote>* Correspondence: christian.devaux@mediterranee-infection.com; Tel.: +33-4-1373-2051</footnote>
(e.g., TMPRSS2) favoring viral ingress, ACE2 is downregulated though several mechanisms, including the shedding of a soluble form of the ectodomain of the molecule (sACE2) [7].

Upon admission to hospital for a SARS-CoV-2 diagnostic, some SARS-CoV-2-positive patients who described themselves as comfortable (patients do not notice any vital signs of collapsed alveoli and air sacs), required special attention: their clinical examination revealed a clinically silent but physiologically proven decrease in the arterial oxygen saturation of hemoglobin (SaO₂), and further examination by low-dose computed tomography (LDCT) showed images compatible with pneumonia. This condition is named 'silent hypoxia', 'asymptomatic hypoxia', or 'happy hypoxia'. Following 'silent hypoxia', untreated COVID-19 patients often develop shortness of breath and dyspnea, which triggers local hypoxia. The prevalence of 'silent hypoxia' in COVID-19 patients ranges from 20% to 40% [8–10]. This 'silent hypoxia' is associated with a very poor outcome, since about one third of these asymptomatic patients should then be transferred to the intensive care unit (ICU); moreover, about one quarter of patients who were transferred to the ICU died from the disease [11]. This simple observation makes it necessary to understand the underlying mechanism of 'silent hypoxia' in an attempt to possibly highlight new targets for the prevention of this asymptomatic pathology. Intervening early enough in this process would avoid a rapid spread of uncontrollable micro-events (e.g., microthrombi in the pulmonary vasculature) promoting multifocal microthrombotic interstitial pneumonitis associated with a slight/moderate intra-alveolar exudate preceding multi-organ dysfunction (including lungs, heart, kidneys, and intestines) [12–14].

If the development of COVID-19 has brought forth the phenomenon of silent hypoxia, this decrease in SaO₂ is a common finding in medicine and is usually precipitated by respiratory disorders or cardiac diseases. It can be observed with diseases such as chronic obstructive pulmonary disease (COPD), pulmonary embolus, atelectasis (collapse of the lung), intrapulmonary shunting (e.g., pulmonary arterivenous malformation, hep-atopulmonary syndrome), intracardiac shunting (e.g., atrial or ventricular septal defects), neurological injury-associated hypoventilation, and obesity-hypoventilation syndrome. Alveolar hypoxia causes hypoxic pulmonary vasoconstriction (HPV) by means of mechanisms local to the lung [15]. The most common mechanism of hypoxia is perfusion through areas that are not well ventilated as a consequence of ventilation-perfusion mismatch (imbalance between the volume of gas expired by the alveoli and the pulmonary capillary blood flow) [16]. Another important cause of hypoxia is left-to-right shunt—a condition in which there is a transfer of blood from the left side of the heart to the right side as a result of a hole in the walls separating the upper chambers (atrium) or lower chambers (ventricles) [17,18]. Hypoxia can also be caused by right ventricular dysfunction following pericardiocentesis [19]. Intraoperative hypoxia following atelectasis is sometimes associated with surgery for abdominal pathology or hip arthroplasty, laryngospasm, and/or inhalational anesthetics [20].

## 2. Clinical Evidence of 'Silent Hypoxia'

Obviously, the ability to maintain O₂ homeostasis is essential for human survival. Up until now, 'silent hypoxia' has been one of the most life-threatening medical problems of COVID-19 [10]. Despite a lack of dyspnea on admission, those patients have hypoxemia/hypocapnia syndrome and are at a high risk of seeing their state of health deteriorate rapidly with irreversible damage to vital organs if left undetected for too long without clinical management (using ventilation with NO gas to improve their SaO₂) [10,11,21]. 'Silent hypoxia' was usually associated with advanced age and comorbidities [22]. Phenotypic differences were observed among patients according to lung elastance, lung recruitability, ventilation-to-perfusion ratio, right-to-left shunt, as well as stress, pain, fear, and anxiety.

The early detection of silent hypoxia in COVID-19 patients is crucial to minimize the risks for severe forms of COVID-19, such as COVID-19-related acute respiratory distress syndrome (C-ARDS), as well as to reduce mortality rate [11,23]. Several reports have revealed that of the COVID-19 patients presenting at the Emergency Department with a
SpO₂ < 90%, the prevalence of silent hypoxia in these patients ranges from 20% to 40%, and that patients with age > 65 years, male sex, high body mass index, cardiac disease, COPD, and high D-dimer are more likely to present with silent hypoxia [10,22,24]. In the Wuhan cohort, 62.4% of severe COVID-19 cases and 46.3% of those who were eventually intubated and ventilated exhibiting sinus tachypnea (increase in normal breathing rate) and higher inflammatory marker levels, or who died, did not present dyspnea [25–27]. Similar observations of shortness of breath have also been reported by other clinicians who suggested the possibility of SARS-CoV-2-induced ACE2 positive neuronal cells death in areas devoted to the sensory perception of dyspnea, or that the cytokine storm associated with the Ang II-AT1R pathway leads to indirect toxic effects on the corticolimbic network [28,29].

In the absence of a prompt medical decision, there is a progressive increase in the occurrence of microvascular thrombi preventing gas exchange in the normally oxygenated areas of tissues leading to the sudden development of hypoxemia in COVID-19 patients. In addition to the formation of fibrin thrombi in tissues where inflammatory cells and platelets are present in abundance, there is also an increased alveolar capillary permeability and exudation into the alveoli, as well as coagulation factors, including fibrinogen. Elevated D-dimers (a biomarker of fibrin degradation) upon patient admission indicate the existence of hypercoagulation and pulmonary embolisms and are associated with increased mortality in severe COVID-19 patients [30–33]. Venous thromboembolism is frequently found to be associated with SARS-CoV-2 infection [34–36]. Therefore, in the most severe forms of the disease, patients suffer from acute respiratory distress syndrome (ARDS) with dyspnea and abnormally ventilated areas of the lungs, resulting in hypoxemia, which has been proven to be associated with hospital mortality [37–39]. This easily recognizable symptomatic phase is likely preceded by an asymptomatic phase (‘silent hypoxia’), during which the molecular crosstalk between the molecules of the RAS orchestrated by the circulation of the virus, free S1 and S1/sACE2 complexes predisposes to the establishment of the symptomatic phase. It has been suggested that ‘silent hypoxia’ is caused by a combination of biological dysfunctions affecting the lungs of COVID-19 patients. These pathological processes include microvascular thrombosis, pulmonary embolisms, ventilation-perfusion mismatching in the non-injured lung, capillary flow redistribution, air sac collapse (atelectasis), flow through intrapulmonary arteriovenous anastomoses, and normal perfusion of the relatively small fraction of injured lungs [40–42]. Before reaching this stage, the pathological process is set up insidiously by deregulation signaling at the level of certain cells (e.g., type II pneumocytes), and then amplified in the microenvironment of those cells. In the initial phase of infection, the virus can enter the peripheral blood stream via the lungs and spread to other organs.

Interestingly, chest computed tomography (CT)-scan abnormalities in people infected with SARS-CoV-2 but who are asymptomatic or pauci-symptomatic have been largely observed, thanks to the wide use of low-dose CT-scans [11]. Most of the patients had some CT-scan abnormalities, mainly as exclusive ground-glass opacities or erratic paving patterns. A key to the good management of COVID-19, especially in patients with risk factors, was to obtain regular oxygen saturation readings by pulse oximetry to enable the early diagnosis of ‘silent hypoxia’ and, consequently, to achieve more appropriate management, including early oxygen supplementation to reduce poor clinical outcomes [43,44]. Although in our experience it has been beneficial for patients, the benefit of adding home pulse oximetry for the remote monitoring of COVID-19 patients is still debated [45]. Regardless, it is imperative that patients be placed under strict day-to-day monitoring [11]. In addition to a pulse oximeter, the other diagnostic tools suitable for identifying the presence of silent hypoxia consist of measuring the arterial blood gas levels and D-dimer [42]. The early detection of silent hypoxia may facilitate the decision on when to start the oxygen treatment or whether to involve an invasive or non-invasive method of oxygenation.
### 3. Regulation of Blood Pressure Homeostasis via the RAS

The angiotensin-converting enzyme 2 (ACE2), which is expressed in a large number of tissues, including endothelial cells of the arteries, arterioles, and venules of the heart and kidney, plays a crucial role in maintaining blood pressure homeostasis, and thus, regulates the pulmonary vascular tone. An imbalance in blood pressure might lead to the development of vascular remodeling and vascular rigidity, which predisposes patients to heart left-ventricular hypertrophy and fibrosis, acute kidney injury, and extensive microthrombosis in coronary and pulmonary circulation [46].

It has been known for decades that ACE2 regulates the balance of two major mediators: angiotensin II (Ang II) and angiotensin-(1-7) (Ang-(1-7) (Figure 1). The regulation of blood pressure by ACE2 is obtained by counteracting the action of ACE1, which hydrolyzes the angiotensin 1 to form Ang II (a mediator of vasoconstriction), while ACE2 transforms the neosynthesized pool of Ang II into Ang-(1-7) (a vasodilator and anti-fibrotic molecule). Ang II is known for enhancing inflammation, fibrosis, and endothelial damage. Ang II binds to the Ang II type I and type II receptors (AT1R and AT2R) [47–50], which are receptors with opposite effects. AT2R is poorly expressed compared to AT1R; therefore, AT1R serves as the major receptor for Ang II-induced cell signals [51,52]. The activation of the Gq coupled receptor AT1R by Ang II is transient and, after phosphorylation by kinases such as PKC and GRKs [53–56], AT1R internalizes through a mechanism that involves β-arrestin 2, the adaptor protein complex 2 (APC2), clathrin, and intersectin 2 [51,57,58]. Through binding to AT1R, Ang II is a potent activator of NADPH oxidase (NOX) and an inducer of reactive oxygen species (ROS) triggering oxidative injury [59]; it also induces proinflammation [60–63]. While many NOX enzymes are localized at least in part at the cell surface where they can release ROS into the extracellular milieu, NOX4 is mainly localized to the endoplasmic reticulum and mitochondria [64]. NOX4, which functions as a constitutively active O₂ sensor, generates H₂O₂ as a function of the cellular oxygen concentration (pO₂). The production of ROS diverts the cytoplasmic pool of HIF-1α from being degraded through the proteasome under control of the prolyl hydroxylase (PHD) and the von Hippel-Lindau gene product (pVHL) E3 ubiquitin ligase, two molecules in charge of maintaining homeostasis [65]. Under Ang II signal, HIF-1α is translocated to the cell nucleus where it modulates the expression of several genes. Furthermore, Ang II inhibits the production of nitric oxide (NO), leading to vascular injury [66]. Finally, the interaction of Ang II with AT1R induces a cascade of events (Rac1, NOX4, ROS, MEK, ERK1/2) leading to the phosphorylation of the p65 subunit of NF-κB, which in turn activates the production of pro-inflammatory molecules [67–69].

<figure><img src="image_5.png" /><figcaption>**Figure 1.** Structure of the renin–angiotensin–(aldosterone) system and the role of ACE2 in this physiological system. ACE1 catalyzes the conversion of angiotensin I (Ang I) to angiotensin II (Ang II). ACE2 catalyzes the conversion of Ang I to angiotensin-(1-9) and the conversion of Ang II to</figcaption></figure>
angiotensin-(1-7). There are also known interactions between the RAS and the Kininogen-(kallikrein)-Bradykinin system (not shown). Under normal physiological conditions, ACE2 converts Ang II into Ang-(1-7), which exhibits vasodilatory, anti-proliferative, and anti-inflammatory effects via the G protein-coupled receptor called Mas-1. Ang-(1-7) counterbalances the vasoconstrictor and inflammatory effect of Ang II. Upon SARS-CoV-2 entry, the downregulation of ACE2 decreases its ability to generate angiotensin (1-9) from Ang I and angiotensin-(1-7) from Ang II, leading to renin–angiotensin system (RAS) imbalance and overactivation of the Ang II-AT1R axis. For more details, see reference [70].

Within the molecular cascade devoted to maintaining blood pressure homeostasis, ACE2 is not the unique effector able lead to the production of Ang-(1-7). Several peptidases, including neprilysin (NEP), vascular endothelium prolyl peptidases, and smooth muscle thimet oligopeptidase, can catalyze the production of Ang-(1-7) [71]. Ang-(1-7) binds to the G protein-coupled receptor (GPGR) named Mas 1 and is characterized by its vasodilating properties and its anti-proliferative and anti-inflammatory effects [72–74]. The activation of MAS 1 induces nitric oxide synthesis.

## 4. The RAS Imbalance in COVID-19

Notably, COVID-19 has a strong vascular component, with microthrombosis events and exacerbated effects on the microvasculature comprising the arterioles, capillaries, and venules. The RAS imbalance determines the clinical outcome of COVID-19 [60,75]. The fact that SARS-CoV-2 enters susceptible human cells by interacting with ACE2 and TMPRSS2 on the surface of lung type II alveolar cells is the central element of the process that leads to RAS imbalance. The down-modulation of ACE2 following its interaction with Sarbecoviruses has been largely documented in vitro [76,77]. The control of ACE2 gene expression is a multifactorial and complex process that has been recently reviewed elsewhere [70]. The binding of SARS-CoV-2 spike S1 to ACE2 triggers an ACE2 ectodomain cleavage by the ADAM17 sheddase [78–80]. The ACE2 cleavages induce the shedding of cellular ACE2 as a soluble form (sACE2) and the systemic release of the S1/sACE2 complex [81]. Moreover, the binding of SARS-CoV-2 to ACE2 is likely to create a steric hindrance at the catalytic site of ACE2, which prevents it from functioning as a peptidase. The inactivation of ACE2 peptidase should lead to the accumulation of Ang II. This is exactly what we previously reported after studying the expression of ACE2 and Ang II in different groups of patients infected with SARS-CoV-2 [82]. We found that COVID-19 patients expressed less ACE2 mRNA, had a lower concentration of plasma sACE2, and had increased plasma levels of Ang II [82]. Although there is still a debate regarding this finding, it was corroborated by most of the other studies that found high increased plasma levels of Ang II in patients with severe COVID-19 [83–85]. This suggests that by decreasing the expression of ACE2 and increasing the number of S1/sACE2 complexes, it is no longer possible to achieve efficient processing of Ang II into Ang-(1-7). A surprising observation was that despite the accumulation/increase in Ang II and the reduction in the capacities of the transformation of Ang II into Ang-(1-7) by ACE2, we found that the plasma level of Ang-(1-7) remained almost constant [82]. Another clinical case report described the same observation with severe COVID-19 patients [86]. The plasma level of Ang-(1-7) can be explained either by the availability of a greater quantity of Ang II to undergoing hydrolysis and producing Ang-(1-7), and/or the action of vascular endothelium prolyl peptidases, neprilysin and smooth muscle thimet oligopeptidase to produce Ang-(1-7) directly from Ang I.

## 5. The Ang II-AT1R-HIF-1α Axis

Under conditions of RAS imbalance and abnormally high plasma concentrations of Ang II, Ang II binds to AT1R and induces an increased production of ROS via the NADPH oxidase, diminishing nitric oxide (NO) bioavailability. [87–89]. Thus, Ang II behaves
as a mediator of oxidative stress, in which reactive oxygen species (ROS) are important signaling intermediates in several signal transduction pathways [90]. This oxidative stress prevented HIF-1α from entering its pathway of degradation through the proteasome. HIF-1α translocates to the cell nucleus and forms a heterodimer with the constitutively expressed HIF-1α to activate gene transcription [91,92]. HIF binds to hypoxia-regulated elements (HREs) in the promoter region of hypoxia-inducible genes as an α/β heterodimer forming a complex with the histone acetyltransferases CBP/p300 [93–95] (Figure 2).

<figure><img src="image_6.png" /><figcaption>**Figure 2.** Schematic diagram illustrating the dual regulation of HIF-1α. (a) At normal O₂ concentration, HIF-1α is hydroxylated by the prolyl hydroxylase (PHD). The ubiquitin ligase VHL targets HIF-1α-OH for polyubiquitinylation and proteosomal degradation. Similarly, hydroxylation of the transient receptor potential channel (TRP) by PHD, and asparaginyl hydroxylase FIH targeting TRP-OH for ubiquitinylation and proteosomal degradation, contribute to homeostasis. (b) Ang II can contribute to hypoxia through binding to AT1R, which initiates signaling events including activation of reactive oxygen species (ROS) by mitochondria. Under hypoxia, HIF-1α translocates to the cell nucleus where it forms heterodimers with the HIF-β subunit and binds to the hypoxia response element (HRE) in the promoter of hypoxia-inducible genes, recruiting histone acetyltransferases CREB Binding Protein (CBP)/p300 to modulate hypoxia-inducible genes expression. For more details, see reference [65].</figcaption></figure>

Several genes are modulated by HIF, including ACE1, myoglobin, endothelial NO synthase, heme oxygenase 2, prolyl hydroxylase 2, FAM213A, lung surfactant protein D, and HIF genes [65,96–98]. HIF-1α also activates the transient receptor potential channel (TRP) ankyrin repeat (TRPA1), which leads to intracellular calcium increase, cytokine release modulation, and cell injury [99–102]. In addition, AT1R signaling modulates Ang II deleterious effects through the activation of multiple downstream pathways (e.g., ERK1/2, NF-κB), some of which lead to the production of specific proinflammatory cytokines (IL-6, IL-1, TNF-α) activation, causing tissue damage [103]. Among these downstream mediators, AT1R is capable of inducing NF-κB, disintegrin, and metalloprotease 17 (ADAM17), altogether promoting the production of TNF-α [104]. This excessive and harmful production of cytokines is known as cytokine storm [105,106]. For example, Liu and colleagues reported
a 67.9% increase in IL-6 in patients with COVID-19 and found that levels of IL-6 and C-reactive protein (CRP, a biomarker of inflammation) in the severe group was significantly higher than in the mild group [107].

Of course, depending on the cell type with which Ang II comes into contact, the Ang II-AT1R-HIF-1α signaling cascade may lead to the expression of a specific subgroup of genes. The consensus DNA sequence for HIF-1α/HIF-1β binding is common for many genes upregulated during hypoxia. It is worth noting that several genes involved in the renin–angiotensin system, in the development and functioning of the vascular system (which modulate vascular tone or promote angiogenesis) and in erythropoiesis, belong to this list (Figure 3). HIF-1α is also known to upregulate p35srj. The p35srj protein is an alternatively spliced isoform of MRG1 which inhibits HIF-1 transactivation by blocking the HIF-1α/p300 interaction. HIF-1α triggers expression of the tyrosine kinase with immunoglobulin and the epidermal growth factor homology domain (Tie2) gene in human coronary microvascular endothelial cells (HCMECs) [108]. The expression of Tie2 (the receptor for angiopoietin 1 and 2) was found to be elevated in COVID-19 patients and may contribute to the angiogenic response in ischemic tissues [109]. Moreover, the Ang II-AT1R interaction also elicits the ADAM17metalloprotease-dependent transactivation of the epidermal growth factor (EGFR) by the heparin-binding EGF-like growth factor (HB-EGF), leading to tyrosine phosphorylation of multiple proteins and the activation of mitogen-activated protein kinase (MAPK/ERK) in various cell types, including vascular smooth muscle cells (VSMC) and hypertrophic responses with a direct action on vascular remodeling [110] (Figure 3).

<figure><img src="image_7.png" /><figcaption>**Figure 3.** Representative list of cellular genes upregulated by HIF-1. HIF-1α is considered a ‘master regulator’ type of transcription factor capable of controlling the expression of a multitude of genes grouped under the heading of hypoxia-inducible genes α (the list is not exhaustive and grows continuously). The consensus DNA sequence for HIF-1α/HIF-1β binding is common for many genes upregulated during hypoxia. It is worth noting that several genes involved in the RAS, in the development and functioning of the vascular system (which modulate vascular tone or promote angiogenesis), and in erythropoiesis, belong to this list.</figcaption></figure>
Moreover, both ACE1 and Ang II play roles in the HIF-1α activation associated with pulmonary hypertension and vascular remodeling [111–113]. The Ang II/AT1R pathway was found to induce marked ACE1 upregulation and ACE2 downregulation in patients with hypertensive cardiopathy associated with the activation of the ERK1/2 and p38 MAP kinase [114–117]. It has been known for many years that HIF-1α is phosphorylated by p42 and p44 mitogen-activated protein kinases (MAPKs also known as ERK1/2), as opposed to by p38 MAPK inducing an upper shift migration of this protein at 12 kDa. It has also been known for a long time that ERK enhances the transcriptional activity of the HIF1 gene [118]. This reinforces the hypothesis that in COVID-19, an excess of Ang II induces signaling via AT1R, which reduces the expression of ACE2 and increases the expression of ACE1, worsening the imbalance of the RAS. This is quite interesting, since we and others found an increase in Ang I production in patients with severe forms of COVID-19 [83,86]. This evokes the progressive establishment of a process of self-amplification in which the increase in ACE1 makes it possible to accumulate more Ang II, and the absence of hydrolysis of this compound by ACE2 makes it possible to maintain high levels of Ang II in the plasma of COVID-19 patients.

## 6. Pathological Consequences of Ang II-AT1R-HIF-1α Axis Activation in COVID-19

The interaction of SARS-CoV-2 with ACE2 causes ACE2 dysfunction, which results in reduced hydrolysis of Ang II and the overproduction/accumulation of Ang II. Ang II produces its harmful effects through the Ang II-AT1R-HIF-1α axis. HIF-1α was found to be activated in alveolar type 2 cells (the main target for SARS-CoV-2 at the early stage of infection) during acute lung injuries [119]. With the activation of HIF-1α, the transcription of ACE1 mRNA is upregulated in pulmonary artery smooth muscle cells [116]. Moreover, Ang II-induced renal injury requires the activation of HIF-1α [120]. The ACE2 mRNA expression is downregulated after 48 h of hypoxia [121] and the plasma Ang II levels increase under hypoxic conditions [122], worsening the patient's clinical condition. Moreover, in COVID-19 patients who develop local hypoxia, HIF-1α nuclear translocation stimulates VEGF production, leading to vascular leakage in endothelial capillary cells [123]. Thus, stabilizing HIF-1α could be one of the ways to act on the outcome of COVID-19 patients, reducing hypoxia and acting on ACE2 expression [124].

The accumulation of such physiological disorders may severely impact the prognosis of COVID-19 patients and increase the risk of death. Therapeutic solutions for reducing COVID-19 severity could be found in the pharmacopoeia used by cardiologists to restore the RAS pathway homeostasis. In healthy humans exposed to isocapnic intermittent hypoxia, a significant increase in SaO₂ was observed, which could be eliminated by treatment with Losartan (a well-known angiotensin II receptor blocker, ARBs, indicated as the first-line antihypertensive drug in patients developing high blood pressure), suggesting a role for AT1R [125]. In addition, AT1R blocking decreases the VEGF expression induced by Ang II [126]. All drugs that have been approved by the Food and Drug Administration (FDA) for treating people with high blood pressure, including renin inhibitors, angiotensin-converting enzyme inhibitors (ACEi), and angiotensin receptor blockers (ARBs), are primarily designed to block or reduce the detrimental effects of Ang II [48,127,128]. Reducing the formation of Ang II by ACEi or blocking the Ang II-AT1R interaction through ARBs may be a suitable strategy for reducing the symptoms of COVID-19 patients [129]. Despite their ability to induce ACE2 expression and potentially promote SARS-CoV-2 infection [130,131], ARBs (e.g., losartan) were found to confer protection against acute lung injury through the reduction in Ang II/AT1R stimulation [132,133]. Previous studies support the beneficial effects of RAS inhibitors in patients with COVID-19 [134,135]. In patients infected with SARS-CoV-2, ARBs are preferred over ACEi for first-line hypertension treatment, and discontinuing treatment is not required [136,137]. Alternatively, the intravenous infusion of 0.4 mg/kg of human recombinant soluble ACE2 (hrsACE2) twice daily may have a beneficial effect [86].
7. The Involvement of Cells, Tissues, and Organs in ‘Silent Hypoxia’

One can intuitively conceive that there is huge spatiotemporal heterogeneity in organ involvement in silent hypoxia, presumably due to the fact that certain organs are exposed in priority to SARS-CoV-2 infection and because multiple pathophysiological mechanisms may be causally involved in the early process of local hypoxia. The main cellular receptor to SARS-CoV-2, ACE2, is expressed in virtually all organs, with higher levels in organs that are richly vascularized, such as the lungs, heart, and kidneys [70,138,139]. In the upper airway, ACE2 expression is highest within regions of the sinonasal cavity and pulmonary alveoli and in the lung parenchyma [5,140]. Remarkably, in the respiratory tract, ACE2 is found on a small subset of alveolar type II epithelial cells thought to be a main target for SARS-CoV-2 [5,6]. These cells share the same basement membrane with closely apposed capillary endothelial cells, also expressing high ACE2 levels. It indicates that alveolar type II epithelial lung cells together with the related capillary endothelium may be a primary site of SARS-CoV-2 infection [141]. Consequently, these cells can be destroyed during viral replication and local tissue damage. In response to SARS-CoV-2 infection of pneumocytes, a process of inflammation is activated, which leads the production of interferon associated with the infiltration of monocyte/macrophages and neutrophils in the lung parenchyma [142]. In addition, the increase in Ang II may have variable effects depending on the specialization of the cells being activated via AT1R (e.g., pneumocytes and immune response cells). Ang II has a significant effect on platelets and the coagulation/fibrinolytic system and causes a mild activation of the coagulation cascade through increased plasma levels of the thrombin–antithrombin complex and prothrombin [143–146]. Moreover, ACE2 catalyzes the conversion of Ang I to Ang-(1-9), the function of which is to reduce plasminogen activator and control fibrinolysis [147]. Finally, SARS-CoV-2 can directly activate platelets by binding to platelet ACE2 [148]. Although patients have relatively well-preserved lung compliance, they experience a compromised pulmonary gas exchange, which leads to a reduced level of oxygenation in the body’s tissues.

The initial clinical presentation of SARS-CoV-2 infection consists of respiratory symptoms such as dry cough, rhinitis, shortness of breath, and, additionally, fever, myalgia, and fatigue. The phase of ‘silent hypoxia’ is a transitional phase during which the more serious pathological consequences of infection are not directly accessible during the clinical examination of the patient. The early pathological manifestation of COVID-19 has a strong vascular component, with exacerbates effects on the microvasculature comprising the arterioles, capillaries, venules, and microthrombosis events. Upon admission of patients, elevated D-dimers (which is a biomarker of the degradation of fibrin and hypercoagulation) highlights a situation of hypercoagulation and pulmonary embolism usually associated with increased mortality in severe COVID-19 patients [32,33]. Increased circulating levels of Ang II are associated with pulmonary inflammation, arterial hypertension, and accelerates thrombosis in arterioles by activating the coagulation cascade and the platelet-derived growth factor (PDGF) [50]. This pattern is detected by peripheral chemical and mechanical sensory receptors located in the aortic arch and the carotid arteries and pulmonary alveolar walls involved in the control of breathing. The gradual increase in the frequency of microvascular thrombi over time leads to a sudden ‘hypoxic spillover’, which initiates the hypoxia phase in COVID-19 patients, since the thrombi prevent gas exchange in the oxygenated areas of tissues. Information from chemical and mechanical sensors together with information from mechanoreceptors located on ribs and muscle tendons are integrated to provide a sensation of dyspnea [149]. Once the system spins out of control, leading to severe COVID-19 and sometimes patient death, the analysis of autopsy lung specimens from COVID-19 patients reveals evidence of inflammatory perivascular lymphocyte infiltration; it documents the existence of microvascular thrombi containing platelets, fibrin, and numerous neutrophil extracellular traps (NETs) releasing [150–152]. Deposits of complement components C3, C4d, and C5b-9 were found in the microvasculature of the lungs [12]. Microangiopathic vessel occlusions and endothelium damage has been observed in the kidneys [153]. In severe COVID-19, heart disease (e.g., cardiomyopathy or myocardial
infarction) as well as other organ pathologies can be observed but remain late with respect to the onset of 'silent hypoxia'.

## 8. Discussion

It is likely that the so-called ‘silent hypoxia’ state corresponds to a situation that does not immediately translate clinically (e.g., shortness of breath and dyspnea), but which is expressed by the occurrence of biological disorders, including: (i) an imbalance of the RAS; (ii) an overproduction of Ang II; and (iii) decreased oxygen saturation readings by pulse oximetry.

Regarding cells, we postulate that ‘silent hypoxia’ corresponds to an activation of the Ang II-AT1R-HIF-1α axis (Figure 4). When SARS-CoV-2 infects a person, the binding of SARS-CoV-2 to ACE2 leads to the dysfunction of ACE2, reduced hydrolysis of Ang II, and increased levels of Ang II. Under this condition, Ang-(1-7) is not sufficient to counterbalance the activity of Ang II. At the single cell level, the binding of Ang II to the AT1R activates phospholipase C (PLC) via the stimulation of G proteins, resulting in the activation of protein kinase C (PKC) in a calcium-dependent manner (and c-Src), which in turn activates NADPH oxidases. NADPH oxidase (NOX) is involved in superoxide (O₂-) production. An increase in cytoplasmic Ca²⁺ through the anion channel (AC) favors the NOX4-induced generation of hydrogen peroxide (H₂O₂), another reactive oxygen species (ROS). It also stimulates the production of ROS by mitochondria and modulates the activity of mitochondrial electron transport chain complex I (mETC-1) producing O₂-. This contributes to the lowering of intracellular oxygen and a reduction in the hydroxylation of HIF-1α by prolyl hydroxylase (PHD), which, under normal conditions, is followed by polyubiquitinylation and proteosomal degradation. It also inhibits the hydroxylation of the TRPA1 transmembrane transporter channel, which leads to increased intracellular Ca²⁺. Under these conditions, HIF-1α translocates to the cell nucleus, forms heterodimers with the HIF-1α, and controls the expression of hypoxia-inducible genes. This leads to the upregulation of the ACE1 gene, which contributes to further increases in Ang II, the increased expression of TRPA1, and to the modulation of expression of various genes. In addition, chronic HIF triggers the downregulation of the ACE2 gene and activation of the metalloproteinase ADAM17, which leads to the cleavage of the ACE2 protein with the release soluble ACE2 (sACE2) and the formation of S1/sACE2 complexes [42,65]. Finally, there is a decrease in nitric oxide (NO) bioavailability, since 02- inactivates NO (Figure 4).

Regarding tissues and organs, the activation of the Ang II-AT1R-HIF-1α axis for an increasing number of cells over time leads to the development of local tissue hypoxia. Hypoxia decreases pulmonary NO and causes vasoconstriction [154]. Notably, the inhalation of NO is known to improve SaO₂ in patients with hypoxic pulmonary vasoconstriction [155]. Peripheral chemical and mechanical sensory receptors located in the aortic arch, the carotid arteries, and the pulmonary alveolar walls, together with mechanoreceptors located on the ribs and muscle tendons, provide signals integrated by the central respiratory pattern generator complex to adapt the cardiovascular response and control of breathing.

Regarding the physiopathology of SARS-CoV-2-infected patients, the virus provokes a molecular disease involving ACE2 downregulation. The most important dysfunctional signaling pathway associated with ‘silent hypoxia’ is related to the RAS dysfunction (ACE1/ACE2 ratio imbalance and abnormal increase in Ang II levels) with its share of adverse consequences on the regulation of blood pressure and coagulation (Figure 5). A computer modeling study [41] revealed that silent hypoxia is likely caused by a combination of biological mechanisms that may occur simultaneously in the lungs of COVID-19 patients. A mismatched air-to-blood flow ratio in parts of the lung that do not appear injured on lung scans (as observed in many respiratory illnesses) starts the process of silent hypoxia aggravated by the presence of blood microclots too small to be seen on medical scans, which can form inside the lungs during the step of inflammation and early tissue damage. The blood flow would indeed have to be much higher than normal in areas of the lungs that can no longer gather oxygen, contributing to lower levels of oxygen throughout the entire
body. While patients may initially achieve cardiorespiratory compensation to hypoxemia, this compensation can fail precipitously. Herman and colleagues [41] suggested that the lungs of these COVID-19 patients had lost the ability of restricting blood flow to already damaged tissue, and in contrast, were potentially opening up those blood vessels even more, something that is hard to see or measure on a CT scan. Moreover, it has been reported that a shunt mechanism by intrapulmonary vascular dilatation (IPVD) is present among patients with severe COVID-19 [156]. We assume that in some patients, a sudden 'hypoxic spillover' marking the tipping point between 'silent hypoxia' and hypoxia leads to localized tissue hypoxia, which may have a tendency to become generalized and leads to a sensation of dyspnea. At this point, tissue damage at the level of one or more organs may gradually reveal itself clinically as COVID-19-related acute respiratory distress syndrome (C-ARDS). In the absence of rapid clinical care using forced ventilation with nitric oxide gas and treatment with anti-coagulants to prevent microthrombi, multifocal tissue damage in the pulmonary alveoli and their microcirculatory environment, the primary cellular insults linked to the extent of the subsequent microvascular thrombo-inflammatory response pose major risks, and these patients may quickly progress to severe COVID-19 (Figure 5).

<figure><img src="image_8.png" /></figure>

**Figure 4.** Proposed model of signaling in SARS-CoV-2-induced silent hypoxia. In order to simplify the representation of the signaling pathways, the effects of Ang II have been summarized on a single cell, but several different cell types are involved in the process of 'silent hypoxia' and can therefore respond in a specific way to Ang II stimulation. When SARS-CoV-2 is present, the binding of SARS-CoV-2 to ACE2 leads to the dysfunction of ACE2, reduced hydrolysis of Ang II, and increased levels of Ang II. Under this condition, Ang-(1-7) is not sufficient to counterbalance the activity of Ang II. The binding of Ang II to the AT1R activates a signaling cascade that contributes to the lowering of intracellular oxygen and a reduction in the hydroxylation of HIF-1α by PHD. Under these conditions, HIF-1α translocates to the cell nucleus, forms heterodimers with the HIF-1α, and controls the expression of hypoxia-inducible genes. This leads to the upregulation of the ACE1 gene, which contributes to further increases in Ang II, the increased expression of TRPA1, and to the modulation of expression of various genes. In addition, chronic HIF triggers the downregulation of the ACE2 gene and the activation of ADAM17, which leads to the cleavage of the ACE2, the release of soluble ACE2 (sACE2), and S1/sACE2 complexes formation. Finally, there is a decrease in nitric oxide (NO) bioavailability, since O₂⁻ inactivates NO.
<figure><img src="image_9.png" /><figcaption>**Figure 5.** Physiologic mechanisms governing the control of breathing. Peripheral chemical and mechanical sensory receptors are involved in the control of breathing and the sensation of dyspnea. Peripheral chemoreceptors located in the aortic arch and the carotid arteries act as sensors for both O₂ tension and CO₂ tension. Pulmonary alveolar walls receptors include joint receptors and stretch receptors. Chemoreceptors in the central and peripheral airways act as irritant sensors. Mechanoreceptors located on the ribs provide information regarding displacement, while muscle tendons provide information regarding tension development. Muscle spindles provide integrated information. The central nervous system integrates these signals and governs breathing (neurons that regulate breathing are widely dispersed in the central cortex, the hypothalamus, the limbic/paralimbic system, pons, and medulla). In moderate hypoxemia, patients respond with intense cardiovascular response (e.g., increased tachycardia, cardiac output, and systemic arterial blood pressure) and accelerated breathing. In contrast, profound hypoxemia (SaO₂ below 50%) is associated with cardiovascular collapse that results in loss of consciousness, bradycardia, and shock. The ‘hypoxic spillover’ corresponds to sudden deterioration in both oxygen saturation and cardiovascular compensation. For more details, see reference [149].</figcaption></figure>

The characterization of the central role of the Ang II-AT1R-ROS-HIF axis in cells that predisposes to the harmful effects of ACE1/ACE2 imbalance and Ang II accumulation, as well as the pharmacological modulation of this signaling pathway, will likely contribute to preventing SARS-CoV-2-positive patients from entering a spiral of deteriorating clinical state. So far, we cannot conclude whether or not having a ‘silent phase’ matters for the Ang II-AT1R-ROS-HIF axis following SARS-CoV-2 infection, but a clinical comparison of survival/mortality in patients with silent hypoxia (phenotype I) and patients with symptomatic hypoxia and clinical signs of acute respiratory failure (phenotype II) indicated higher ICU mortality (29.2% vs. 18.8%, *p* < 0.014) and in-hospital mortality (32.5% vs. 18.8%, *p* < 0.002) in phenotype II (however, a multivariate analysis showed that the cause of silent hypoxia was not clearly identified) [157].

In patients with hypertension hospitalized for COVID-19, a systematic review and meta-analysis suggest that the prior use of RAS inhibitors is associated with a lower risk of mortality, and this has led to the recommendation (current treatment guidelines) that
patients taking RAS inhibitors to manage hypertension should continue their treatment when infected by SARS-CoV-2 [46,158]. In addition to the now classic approach of patient ventilation as soon as oxygen saturation monitored by pulse oximetry indicates that SpO2 is 94% or below on two occasions, identifying the cause of 'silent hypoxia' at the molecular level makes it possible to consider other early therapeutic strategies that can benefit patients, such as ACEi, ARBs, human recombinant soluble ACE2 (hrsACE2) and, possibly in the future, molecules acting on HIF-1α homeostasis. Notably, Wing and colleagues reported that hypoxia and the HIF prolyl hydroxylase inhibitor FG4592/Roxadustat reduce ACE2 expression and inhibit SARS-CoV-2 entry and replication in lung epithelial cells via an HIF-1α-dependent pathway [159]. They also reported that the pharmacological activation of HIF with FG-4592/Roxadustat significantly reduced epithelial damage and respiratory symptoms in a Syrian hamster model of SARS-CoV-2 infection and increased the expression of ciliated cells [160]. However, care must be taken with this type of molecule because of the pleiotropic role of activated HIF-1α. Indeed, adverse effects of HIF-1α associated with activation on infection and pro-inflammatory responses, epileptogenesis, and pronounced and persistent defects of B cells in COVID-19 patients have also been reported [161–163]. This discrepancy between the beneficial and harmful effects of HIF-1α activation in COVID-19 may be due to cell-specific HIF signaling during SARS-CoV2 infection.

COVID-19 is driving large numbers of severely hypoxemic patients to medical care and highlighting the phenomenon of 'silent hypoxia' during the early phase of the disease. Here, we attempted to specify how molecular disorders at the level of the cell, followed by tissue damage, lead to a sudden transition from compensated to poorly compensated cardiovascular adaptation to hypoxemia at the level of the infected individual, a phenomenon we named 'hypoxic spillover'. The analysis of the molecular process that leads to C-ARDS makes it possible to imagine new therapeutic approaches in the treatment of COVID-19 which could be added to the panoply of therapeutic strategies currently available to clinicians.

**Author Contributions:** Both authors contributed to the design of the review. C.A.D. wrote the manuscript and both C.A.D. and J.-C.L. agreed with the manuscript submitted for publication. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research was funded by the French Government under the «Investissements d'avenir» (Investments for the Future) program managed by the Agence Nationale de la Recherche (French National Agency for Research) (reference: Méditerranée Infection 10-IAHU-03), and annual funding from Aix-Marseille university and IRD to the MEPHI research unit.

**Institutional Review Board Statement:** This study did not require ethical approval.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** No new data were created.

**Acknowledgments:** We thank Didier Raoult for stimulating and helpful discussions. The figures were designed using the Servier Medical Art supply of images available under a Creative Commons CC BY 3.0 license.

**Conflicts of Interest:** C.A.D. declares a link of interest with the Sanofi and Merck pharmaceutical companies. J.-C.L. declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

## References

1. Zhou, P.; Yang, X.-L.; Wang, X.-G.; Hu, B.; Zhang, L.; Zhang, W.; Si, H.-R.; Zhu, Y.; Li, B.; Huang, C.-L.; et al. A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin. *Nature* **2020**, *579*, 270–273. [CrossRef]

2. Zhu, N.; Zhang, D.; Wang, W.; Li, X.; Yang, B.; Song, J.; Zhao, X.; Huang, B.; Shi, W.; Lu, R.; et al. A Novel Coronavirus from patients with pneumonia in China, 2019. *N. Engl. J. Med.* **2020**, *382*, 727–733. [CrossRef]

3. Yan, R.; Zhang, Y.; Li, Y.; Xia, L.; Guo, Y.; Zhou, Q. Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. *Science* **2020**, *367*, 1444–1448. [CrossRef]
4. Qiu, Y.; Zhao, Y.-B.; Wang, Q.; Li, J.-Y.; Zhou, Z.-J.; Liao, C.-H.; Ge, X.-Y. Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2. *Microbes Infect.* **2020**, *22*, 221–225. [CrossRef]

5. Ortiz, M.E.; Thurman, A.; Pezzulo, A.A.; Leidinger, M.R.; Klesney-Tait, J.A.; Karp, P.H.; Tan, P.; Wohlford-Lenane, C.; McCray, P.B.; Meyerholz, D.K. Heterogeneous expression of the SARS Coronavirus-2 receptor ACE2 in the human respiratory tract. *EBioMedicine* **2020**, *60*, 102976. [CrossRef]

6. Delorey, T.M.; Ziegler, C.G.K.; Heimberg, G.; Normand, R.; Yang, Y.; Segerstolpe, A.; Abbondanza, D.; Fleming, S.J.; Subramanian, A.; Montoro, D.T.; et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature* **2021**, *595*, 107–113. [CrossRef]

7. Devaux, C.A.; Rolain, J.M.; Raoult, D. ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. *J. Microbiol. Immunol. Inf.* **2020**, *53*, 425–435. [CrossRef] [PubMed]

8. Fuglebjerg, N.; Jensen, T.; Hoyer, N.; Ryrso, C.; Madsen, B.; Harboe, Z. Silent hypoxia in patients with SARS CoV-2 infection before hospital discharge. *Int. J. Infect. Dis.* **2020**, *99*, 100–101. [CrossRef]

9. Tobin, M.; Laghi, F.; Jubran, A. Why COVID-19 silent hypoxemia Is baffling to physicians. *Am. J. Respir. Crit. Care Med.* **2020**, *202*, 356–360. [CrossRef]

10. Couzin-Frankel, J. The mystery of the pandemic's 'happy hypoxia'. *Science* **2020**, *368*, 455–456. [CrossRef]

11. Brouqui, P.; Amrane, S.; Million, M.; Cortaredona, S.; Parola, P.; Lagier, J.-C.; Raoult, D. Asymptomatic hypoxia in COVID-19 is associated with poor outcome. *Int. J. Infect. Dis.* **2021**, *102*, 233–238. [CrossRef] [PubMed]

12. Magro, C.; Mulvey, J.J.; Berlin, D.; Nuovo, G.; Salvatore, S.; Harp, J.; Baxter-Stoltzfus, A.; Laurence, J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. *Transl. Res.* **2020**, *220*, 1–13. [CrossRef]

13. Gusmao Ramos, S.; da Cruz Rattis, B.A.; Ottaviani, G.; Nunes Celes, M.R.; Pedra Dias, E. ACE2 Down-Regulation May Act as a Transient Molecular Disease Causing RAAS Dysregulation and Tissue Damage in the Microcirculatory Environment Among COVID-19 Patients. *Am. J. Pathol.* **2021**, *191*, 1154–1166. [CrossRef] [PubMed]

14. Osman, I.O.; Garrec, C.; de Souza, G.A.P.; Zarubica, A.; Belhaouari, D.B.; Baudoin, J.-P.; Lepidi, H.; Mege, J.-L.; Malissen, B.; La Scola, B.; et al. Control of CDH1/E-Cadherin Gene Expression and Release of a Soluble Form of E-Cadherin in SARS-CoV-2 Infected Caco-2 Intestinal Cells: Physiopathological Consequences for the Intestinal Forms of COVID-19. *Front. Cell. Infect. Microbiol.* **2022**, *12*, 798767. [CrossRef] [PubMed]

15. Sylvester, J.T.; Shimoda, L.A.; Aaronson, P.I.; Ward, J.P.T. Hypoxic pulmonary vasoconstriction. *Physiol. Rev.* **2012**, *92*, 367–520. [CrossRef]

16. Boerrigter, B.G.; Boonstra, A.; Westerhof, N.; Postmus, P.E.; Vonk-Noordegraaf, A. Cardiac shunt in COPD as a cause of severe hypoxaemia: Probably not so uncommon after all. *Eur. Respir. J.* **2011**, *37*, 960–970. [CrossRef]

17. Vodoz, J.-F.; Cottin, V.; Glérant, J.-C.; Derumeaux, G.; Khouatra, C.; Blanchet, A.-S.; Mastroïanni, B.; Bayle, J.-Y.; Mornex, J.-F.; Cordier, J.-F. Right-to-left shunt with hypoxemia in pulmonary hypertension. *BMC Cardiovasc. Disord.* **2009**, *9*, 15. [CrossRef]

18. Lau, V.I.; Mah, G.D.; Wang, X.; Byker, L.; Robinson, A.; Milovanovic, L.; Alherbish, A.; Odenbach, J.; Vadeanu, C.; Lu, D.; et al. Intra-pulmonary and intra-cardiac shunts in adult COVID-19 versus non-COVID ARDS ICU patients using echocardiography and contrast bubble studies (COVID-Shunt Study): A prospective, observational cohort study. *MedRxiv*, 2022, preprint. [CrossRef]

19. Sharaf, M.; Rajaram, M.; Mulji, A. Intracardiac shunt with hypoxemia caused by right ventricular dysfunction following pericardiocentesis. *Can. J. Cardiol.* **2008**, *24*, e60–e62. [CrossRef]

20. Ji, J.Y.; Chung, J.H.; Kim, N.S.; Seo, Y.H.; Jung, H.S.; Chun, H.R.; Gong, H.Y.; Kim, W.J.; Ahn, J.M.; Park, Y.J. Causes and treatment of hypoxia during total hip arthroplasty in elderly patients: A case report. *Int. J. Environ. Res. Public Health* **2021**, *18*, 12931. [CrossRef]

21. Machluf, Y.; Rosenfeld, S.; Ben Shlomo, I.; Chaiter, Y.; Dekel, Y. The misattributed and silent causes of poor COVID-19 outcomes among pregnant women. *Front. Med.* **2021**, *8*, 745797. [CrossRef]

22. Bepouka, B.; Odio, O.; Mayasi, N.; Longokolo, M.; Mangala, D.; Mandina, M.; Mbula, M.; Kayembe, J.M.; Situakibanza, H. Prevalence and outcomes of COVID-19 patients with happy hypoxia: A systematic review. *Infect. Drug Resist.* **2022**, *15*, 5619–5628. [CrossRef] [PubMed]

23. Masi, P.; Bagate, F.; d'Humières, T.; Al-Assaad, L.; Abou Chakra, L.; Derumeaux, G.; Mekontso Dessap, A. Is hypoxemia explained by intracardiac or intrapulmonary shunt in COVID-19-related acute respiratory distress syndrome? *Ann. Intensive Care* **2020**, *10*, 108. [CrossRef]

24. Alhusain, F.; Alromaih, A.; Alhajress, G.; Alsaghyir, A.; Alqobaisi, A.; Alaboodi, T.; Alsalamah, M. Predictors and clinical outcomes of silent hypoxia in COVID-19 patients, a single-center retrospective cohort study. *J. Inf. Public Health* **2021**, *14*, 1595–1599. [CrossRef]

25. Guan, W.J.; Ni, Z.Y.; Hu, Y.; Liang, W.H.; Qu, C.Q.; He, J.X.; Liu, L.; Shan, H.; Lei, C.L.; Hui, D.S.C.; et al. Clinical characteristics of coronavirus disease 2019 in China. *N. Engl. J. Med.* **2020**, *382*, 1708–1720. [CrossRef] [PubMed]

26. Li, Y.C.; Bai, W.Z.; Hashikawa, T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. *J. Med. Virol.* **2020**, *92*, 552–555. [CrossRef]

27. Hsieh, J.Y.C.; Kan, J.Y.L.; Mattar, S.A.M.; Qin, Y. The clinical implications of sinus tachycardia in mild COVID-19 infection: A retrospective cohort study. *SAGE Open Med.* **2021**, *9*, 1–6. [CrossRef]
28. Recasens, B.B.; Martinez-Llorens, J.M.; Rodriguez-Sevilla, J.J.; Rubio, M.A. Lack of dyspnea in patients with COVID-19: Another neurological conundrum? *Eur. J. Neurol.* **2020**, *27*, e40. [CrossRef]

29. De Vito, E.L. Possible role of corollary discharge in lack of dyspnea in patients with COVID-19 disease. *Front. Physiol.* **2021**, *12*, 719166. [CrossRef] [PubMed]

30. Lippi, G.; Favaloro, E.J. D-Dimer is associated with severity of coronavirus disease 2019: A pooled analysis. *Thromb. Haemostasis* **2020**, *120*, 876-878. [CrossRef]

31. Sakka, M.; Connors, J.M.; He'kimian, G.; Martin-Toutain, I.; Crichi, B.; Colmegna, I.; Bonnefont-Rousselot, D.; Farge, D.; Frere, C. Association between D-dimer levels and mortality in patients with coronavirus disease 2019 COVID19: A systematic review and pooled analysis. *J. Med. Vasc.* **2020**, *45*, 268-274. [CrossRef] [PubMed]

32. Smadja, D.M.; Mentzer, S.J.; Fontenay, M.; Laffan, M.A.; Ackermann, M.; Helms, J.; Jonigk, D.; Chocron, R.; Pier, G.B.; Gendron, N.; et al. COVID-19 is a systemic vascular hemopathy: Insight for mechanistic and clinical aspects. *Angiogenesis* **2021**, *24*, 755-788. [CrossRef]

33. Stefely, J.A.; Christensen, B.B.; Gogakos, T.; Sullivan, J.K.C.; Montgomery, G.G.; Barranco, J.P.; Van Cott, E.M. Marked factor V activity elevation in severe COVID-19 is associated with venous thromboembolism. *Am. J. Hematol.* **2020**, *95*, 1522-1530. [CrossRef] [PubMed]

34. Middeldorp, S.; Coppens, M.; van Haaps, T.F.; Foppen, M.; Vlaar, A.P.; Miller, M.C.A.; Bouman, C.C.S.; Beenen, L.F.M.; Kootte, R.S.; Heijmanset, J. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *J. Thromb. Haemost.* **2020**, *18*, 1995-2002. [CrossRef] [PubMed]

35. Léonard-Lorant, I.; Delabranche, X.; Séverac, F.; Helms, J.; Pauzet, C.; Collange, O.; Schneider, F.; Labani, A.; Bilbault, P.; Molière, S.; et al. Acute pulmonary embolism in COVID-19 patients on CT angiography and relationship to D-dimer levels. *Radiology* **2020**, *296*, E189-E191. [CrossRef]

36. Faggiano, P.; Bonelli, A.; Paris, S.; Milesi, G.; Bisegna, S.; Bernardi, N.; Curnis, A.; Agricola, E.; Maroldi, R. Acute Pulmonary Embolism in COVID-19 Disease: Preliminary Report on Seven Patients. *Int. J. Cardiol.* **2020**, *313*, 129-131. [CrossRef]

37. Wu, C.; Chen, X.; Cai, Y.; Xia, J.; Zhou, X.; Xu, S.; Huang, H.; Zhang, L.; Zhou, X.; Du, C.; et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. *JAMA Intern. Med.* **2020**, *180*, 934-943. [CrossRef]

38. Kashani, K.B. Hypoxia in COVID-19: Sign of Severity or Cause for Poor Outcomes. *Mayo Clin. Proc.* **2020**, *95*, 1094-1096. [CrossRef]

39. Xie, J.; Covassin, N.; Fan, Z.; Singh, P.; Gao, W.; Li, G.; Kara, T.; Somers, V.K. Association between hypoxemia and mortality in patients with COVID-19. *Mayo Clin. Proc.* **2020**, *95*, 1138-1147. [CrossRef]

40. Nitsure, M.; Sarangi, B.; Shankar, G.H.; Reddy, V.S.; Walimbe, A.; Sharma, V.; Prayag, S. Mechanisms of Hypoxia in COVID-19 Patients: A Pathophysiologic Reflection. *Indian J. Crit. Care Med.* **2020**, *24*, 967-970. [CrossRef]

41. Herrmann, J.; Mori, V.; Bates, J.H.T.; Suki, B. Modeling lung perfusion abnormalities to explain early COVID-19 hypoxemia. *Nature Com.* **2020**, *11*, 4883. [CrossRef]

42. Rahman, A.; Tabassum, T.; Araf, Y.; Al Nahid, A.; Ullah, M.A.; Jakir Hosen, M. Silent hypoxia in COVID-19: Pathomechanism and possible management strategy. *Mol. Biol. Rep.* **2021**, *48*, 3863-3869. [CrossRef]

43. Singh, A.; Kataria, S.; Das, P.; Sharma, A. A proposal to make the pulse oximetry as omnipresent as thermometry in public health care systems. *J. Glob. Health* **2020**, *10*, 0203102. [CrossRef]

44. Huynh, D.N.; Millan, A.; Quijada, E.; John, D.; Khan, S.; Funahashi, T. Description and early results of the Kaiser Permanente Southern California COVID-19 home monitoring program. *Perm. J.* **2021**, *25*, 20.281. [CrossRef]

45. Lee, K.C.; Morgan, A.U.; Chaiyachati, K.H.; Asch, D.A.; Xiong, R.A.; Do, D.; Kilaru, A.S.; Lam, D.; Parambath, A.; Friedman, A.B.; et al. Pulse oximetry for monitoring patients with Covid-19 at home—A pragmatic, randomized trial. *N. Engl. J. Med* **2022**, *386*, 19. [CrossRef]

46. Gallo, G.; Calvez, V.; Savoia, C. Hypertension and COVID-19: Current evidence and perspectives. *High Blood Pressure Cardiovasc. Prevent.* **2022**, *29*, 115-123. [CrossRef]

47. Wakahara, S.; Konoshita, T.; Mizuno, S.; Motomura, M.; Aoyama, C.; Makino, Y.; Kato, N.; Koni, I.; Miyamori, I. Synergistic expression of angiotensin-converting enzyme (ACE) and ACE2 in human renal tissue and confounding effects of hypertension on the ACE to ACE2 Ratio. *Endocrinology* **2007**, *148*, 2453-2457. [CrossRef]

48. Arendse, L.B.; Danser, A.H.J.; Poglitsch, M.; Touyz, R.M.; Burnett, J.C., Jr.; Llorens-Cortes, C.; Ehlers, M.R.; Sturrock, E.D. Novel therapeutic approaches targeting the Renin-Angiotensin System and associated peptides in hypertension and heart failure. *Pharmacol. Rev.* **2019**, *71*, 539-570. [CrossRef]

49. Gustafsson, F.; Holstein-Rathlou, N.H. Angiotensin II modulates conducted vasoconstriction to norepinephrine and local electrical stimulation in rat mesenteric arterioles. *Cardiovasc. Res.* **1999**, *44*, 176-184. [CrossRef]

50. Samavati, L.; Uhal, B.D. ACE2, much more than just a receptor for SARS-COV-2. *Front. Cell. Infect. Microbiol.* **2020**, *10*, 317. [CrossRef]

51. Forrester, S.J.; Booz, G.W.; Sigmund, C.D.; Coffman, T.M.; Kawai, T.; Rizzo, V.; Scalia, R.; Eguchi, S. Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology. *Physiol. Rev.* **2018**, *98*, 1627-1738. [CrossRef] [PubMed]
52. Furuhashi, M.; Moniwa, N.; Takizawa, H.; Ura, N.; Shimamoto, K. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19. *Hypertens. Res.* **2020**, *43*, 837–840. [CrossRef] [PubMed]

53. Sadoshima, J.; Qiu, Z.; Morgan, J.P.; Izumo, S. Angiotensin-II and other hypertrophic stimuli mediated by G-protein-coupled receptors activate tyrosine kinase, mitogen-activated protein-kinase, and 90-Kd S6 kinase in cardiac myocytes—The critical role of Ca²⁺-dependent signaling. *Circ. Res.* **1995**, *76*, 1–15. [CrossRef] [PubMed]

54. Han, Y.; Runge, M.S.; Brasier, A.R. Angiotensin II induces Interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear Factor-κB transcription Factors. *Circ. Res.* **1999**, *84*, 695–703. [CrossRef]

55. Rushworth, C.A.; Guy, J.L.; Turner, A.J. Residues affecting the chloride regulation and substrate selectivity of the angiotensin-converting enzymes (ACE and ACE2) identified by site-directed mutagenesis. *FEBS J.* **2008**, *275*, 6033–6042. [CrossRef]

56. Luther, J.; Gainer, J.V.; Murphey, L.J.; Yu, C.; Vaughan, D.E.; Morrow, J.D.; Brown, N.J. Angiotensin II Induces Interleukin-6 in Humans Through a Mineralocorticoid Receptor-Dependent Mechanism. *Hypertension* **2006**, *48*, 1050–1057. [CrossRef]

57. AbdAlla, S.; Lother, H.; Quitterer, U. AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature* **2000**, *407*, 94–98. [CrossRef]

58. Gáborik, Z.; Szaszák, M.; Szidonya, L.; Balla, B.; Paku, S.; Catt, K.J.; Clark, A.J.L.; Hunyady, L. Beta-arrestin- and dynamin-dependent endocytosis of the AT1 angiotensin receptor. *Mol. Pharmacol.* **2001**, *59*, 239–247. [CrossRef]

59. Garrido, A.M.; Griendling, K.K. NADPH Oxidases and Angiotensin II Receptor Signaling. *Mol. Cell. Endocrinol.* **2009**, *302*, 148–158. [CrossRef]

60. Nataraj, C.; Oliverio, M.I.; Mannon, R.B.; Mannon, P.J.; Audoly, L.P.; Amuchastegui, C.S.; Ruiz, P.; Smithies, O.; Coffman, T.M. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. *J. Clin. Investig.* **1999**, *104*, 1693–1701. [CrossRef]

61. Ruiz-Ortega, M.; Lorenzo, O.; Suzuki, Y.; Rupérez, M.; Egido, J. Proinflammatory actions of angiotensins. *Curr. Opin. Nephrol. Hypertens.* **2001**, *10*, 321–329. [CrossRef]

62. Watanabe, T.; Barker, T.A.; Berk, B.C. Angiotensin II and the endothelium: Diverse signals and effects. *Hypertension* **2005**, *45*, 163–169. [CrossRef]

63. Dikalov, S.I.; Nazarewicz, R.R. Angiotensin II-Induced Production of Mitochondrial Reactive Oxygen Species: Potential Mechanisms and Relevance for Cardiovascular Disease. *Antioxid. Redox Signal.* **2013**, *19*, 1085–1094. [CrossRef]

64. Nisimoto, Y.; Diebold, B.A.; Cosentino-Gomes, D.; Lambeth, J.D. Nox4: A Hydrogen Peroxide-Generating Oxygen Sensor. *Biochemistry* **2014**, *53*, 5111–5120. [CrossRef]

65. Devaux, C.A.; Raoult, D. The impact of COVID-19 on populations living at high altitude: Role of hypoxiainducible factors (HIFs) signaling pathway in SARS-CoV-2 infection and replication. *Front. Physiol.* **2022**, *13*, 960308. [CrossRef]

66. Abu Nabah, Y.N.; Mateo, T.; Estellés, R.; Mata, M.; Zagorski, J.; Sarau, H.; Cortijo, J.; Morcillo, E.J.; Jose, P.J.; Sanz, M.-J.; et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. *Circulation* **2004**, *110*, 3581–3586. [CrossRef]

67. Jamaluddin, M.; Meng, T.; Sun, J.; Boldogh, I.; Han, Y.; Brasier, A.R. Angiotensin II induces nuclear factor (NF)-kappaB1 isoforms to bind the angiotensinogen gene acute-phase response element: A stimulus-specific pathway for NF-kappaB activation. *Mol. Endocrinol.* **2000**, *14*, 99–113.

68. Skurk, T.; van Harmelen, V.; Hauner, H. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB. *Arterioscler. Thromb. Vasc. Biol.* **2004**, *24*, 1199–1203. [CrossRef]

69. Gorin, Y.; Ricono, J.M.; Wagner, B.; Kim, N.H.; Bhandari, B.; Choudhury, G.G. Angiotensin II-induced ERK1/ERK2 activation and protein synthesis are redox-dependent in glomerular mesangial cells. *Biochem. J.* **2004**, *381*, 231–239. [CrossRef]

70. Devaux, C.A.; Camoin-Jau, L. An update on ACE2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of COVID-19: Implications for vascular and coagulation disease associated with SARS-CoV-2 infection. *Front. Microbiol.* **2022**, *13*, 1042200. [CrossRef]

71. Chappell, M.C. The Angiotensin-(1-7) Axis: Formation and Metabolism Pathways. In *Angiotensin-(1-7)*; Santos, R.A.S., Ed.; Springer Nature Switzerland: Cham, Switzerland, 2019; Volume 22, pp. 1–26. [CrossRef]

72. Santos, R.A.; Simoes e Silva, A.C.; Maric, C.; Silva, D.M.R.; Machado, R.P.; de Buhr, I.; Heringer-Walther, S.; Pinheiro, S.V.B.; Lopes, M.T.; Bader, M.; et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc. Natl. Acad. Sci. USA* **2003**, *100*, 8258–8263. [CrossRef] [PubMed]

73. Santos, R.A.S.; Sampaio, W.O.; Alzamora, A.C.; Motta-Santos, D.; Alenina, N.; Bader, M.; Campagnole-Santos, M.J. The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: Focus on angiotensin-(1-7). *Physiol. Rev.* **2018**, *98*, 505–553. [CrossRef] [PubMed]

74. Bader, M.; Alenina, N.; Young, D.; Santos, R.A.S.; Touyz, R.M.; Savergnini, S.Q.; Beiman, M.; Lautner, R.Q.; de Paula-Carvalho, V.; Allahdadi, K.; et al. The meaning of Mas. *Hypertension* **2018**, *72*, 1072–1075. [CrossRef] [PubMed]

75. Rysz, S.; Al-Saadi, J.; Sjöström, A.; Farm, M.; Jalde, F.C.; Plattén, M.; Eriksson, H.; Klein, M.; Vargas-Paris, R.; Nyrén, S.; et al. COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone system. *Nat. Com.* **2021**, *12*, 2417. [CrossRef]

76. Kuba, K.; Imai, Y.; Rao, S.; Gao, H.; Guo, F.; Guan, B.; Huan, Y.; Yang, P.; Zhang, Y.; Deng, W.; et al. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. *Nat. Med.* **2005**, *11*, 875–879. [CrossRef]
77. Qiao, Y.; Wang, X.-M.; Mannan, R.; Pitchiaya, S.; Zhang, Y.; Wotring, J.W.; Xiao, L.; Robinson, D.R.; Wu, Y.-M.; Tien, J.C.-Y.; et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. *Proc. Natl. Acad. Sci. USA* **2021**, *118*, e2021450118. [CrossRef]

78. Heurich, A.; Hofmann-Winkler, H.; Gierer, S.; Liepold, T.; Jahn, O.; Pöhlmann, S. TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein. *J. Virol.* **2014**, *88*, 1293–1307. [CrossRef]

79. Lambert, D.W.; Yarski, M.; Warner, F.J.; Thornhill, P.; Parkin, E.T.; Smith, A.I.; Hooper, N.M.; Turner, A.J. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). *J. Biol. Chem.* **2005**, *280*, 30113–33019. [CrossRef]

80. Oarhe, C.I.; Dang, V.; Dang, M.; Nguyen, H.; Gopallawa, I.; Gewolb, I.H.; Uhal, B.D. Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts. *Pediatr. Res.* **2015**, *77*, 656–662. [CrossRef]

81. Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.-H.; Nitsche, A.; et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. *Cell* **2020**, *181*, 271–280.e8. [CrossRef] [PubMed]

82. Osman, I.O.; Melenotte, C.; Brouqui, P.; Million, M.; Lagier, J.-C.; Parola, P.; Stein, A.; La Scola, B.; Meddeb, L.; Mege, J.-L.; et al. Expression of ACE2, Soluble ACE2, Angiotensin I, Angiotensin II and Angiotensin-(1-7) Is Modulated in COVID-19 Patients. *Front. Immunol.* **2021**, *12*, 625732. [CrossRef] [PubMed]

83. Wu, Z.; Hu, R.; Zhang, C.; Ren, W.; Yu, A.; Zhou, X. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. *Crit. Care* **2020**, *24*, 290. [CrossRef]

84. Liu, Y.; Yang, Y.; Zhang, C.; Huang, F.; Wang, F.; Yuan, J.; Wang, Z.; Li, J.; Li, J.; Feng, C.; et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. *Sci. China Life Sci.* **2020**, *63*, 364–374. [CrossRef]

85. Reindl-Schwaighofer, R.; Hödlmoser, S.; Eskandary, F.; Poglitsch, M.; Bonderman, D.; Strassl, R.; Aberle, J.H.; Oberbauer, R.; Zoufaly, A.; Hecking, M. ACE2 Elevation in Severe COVID-19. *Am. J. Resp. Critic. Care Med.* **2021**, *203*, 1191–1196. [CrossRef] [PubMed]

86. Zoufaly, A.; Poglitsch, M.; Aberle, J.H.; Hoepler, W.; Seitz, T.; Traugott, M.; Grieb, A.; Pawelka, E.; Laferl, H.; Wenisch, C.; et al. Human Recombinant Soluble ACE2 in Severe COVID-19. *Lancet Resp. Med.* **2020**, *8*, 115–120. [CrossRef] [PubMed]

87. Griendling, K.K.; Minieri, C.A.; Ollerenshaw, J.D.; Alexander, R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. *Circ. Res.* **1994**, *74*, 1141–1148. [CrossRef]

88. Rajagopalan, S.; Kurz, S.; Münzel, T.; Tarpey, M.; Freeman, B.A.; Griendling, K.K.; Harrison, D.G. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. *J. Clin. Investig.* **1996**, *97*, 1916–1923. [CrossRef] [PubMed]

89. Dandona, P.; Kumar, V.; Aljada, A.; Ghanim, H.; Syed, T.; Hofmayer, D.; Mohanty, P.; Tripathy, D.; Garg, R. Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-kappa B, in mononuclear cells of normal subjects: Evidence of an antiinflammatory action. *J. Clin. Endocrinol. Metab.* **2003**, *88*, 4496–4501. [CrossRef]

90. Duprez, D.A. Role of the renin-angiotensin-aldosterone system in vascular remodeling and inflammation: A clinical review. *J. Hypertens.* **2006**, *24*, 983–991. [CrossRef]

91. Ratcliffe, P.J. Oxygen sensing and hypoxia signalling pathways in animals: The implications of physiology for cancer. *J. Physiol.* **2013**, *591*, 2027–2042. [CrossRef] [PubMed]

92. Maxwell, P.H.; Wiesener, M.S.; Chang, G.-W.; Clifford, S.C.; Vaux, E.C.; Cockman, M.E.; Wykoff, C.C.; Pugh, C.W.; Maher, E.R.; Ratcliffe, P.J. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. *Nature* **1999**, *399*, 271–275. [CrossRef]

93. Wang, G.L.; Jiang, B.-H.; Rue, E.A.; Semenza, G.L. Hypoxia-inducible factor 1 is a basic-helix-loop-helixPAS heterodimer regulated by cellular O₂ tension. *Proc. Natl. Acad. Sci. USA* **1995**, *92*, 5510–5514. [CrossRef]

94. Kallio, P.J.; Okamoto, K.; O'Brien, S.; Carrero, P.; Makino, Y.; Tanaka, H.; Poellinger, L. Signal transduction in hypoxic cells: Inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia-inducible factor-1α. *EMBO J.* **1998**, *17*, 6573–6586. [CrossRef]

95. Dames, S.A.; Martinez-Yamout, M.; De Guzman, R.N.; Dyson, H.J.; Wright, P.E. Structural basis for Hif-1α/CBP recognition in the cellular hypoxic response. *Proc. Natl. Acad. Sci. USA* **2002**, *99*, 5271–5276. [CrossRef]

96. Gesang, L.; Liu, G.; Cen, W.; Qiu, C.; Zhuoma, C.; Zhuang, L.; Ren, D.; Pincuo, Z.; Chan, Y. Angiotensin-converting enzyme gene polymorphism and its association with essential hypertension in a Tibetan population. *Hypertens. Res.* **2002**, *25*, 481–485. [CrossRef]

97. Beall, C.M.; Cavalleri, G.L.; Deng, L.; Elston, R.C.; Gao, Y.; Knight, J.; Li, C.; Li, J.C.; Liang, Y.; McCormack, M.; et al. Natural selection on EPAS1 (HIF2α) associated with low hemoglobin concentration in Tibetan highlanders. *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 11459–11464. [CrossRef]

98. Semenza, G.L. HIF-1: Mediator of physiological and pathophysiological responses to hypoxia. *J. Appl. Physiol.* **2000**, *88*, 1474–1480. [CrossRef]

99. Seta, K.A.; Yuan, Y.; Spicer, Z.; Lu, G.; Bedard, J.; Ferguson, T.K.; Pathrose, P.; Cole-Strauss, A.; Kaufhold, A.; Millhorn, D.E. The role of calcium in hypoxia-induced signal transduction and gene expression. *Cell Calcium* **2004**, *36*, 331–340. [CrossRef]
100. Hatano, N.; Itoh, Y.; Suzuki, H.; Muraki, Y.; Hayashi, H.; Onozaki, K.; Wood, I.C.; Beech, D.J.; Muraki, K. Hypoxia-inducible factor-1α (HIF1α) switches on transient receptor potential ankyrin repeat 1 (TRPA1) gene expression via a hypoxia response element-like motif to modulate cytokine release. *J. Biol. Chem.* **2012**, *287*, 31962–31972. [CrossRef]

101. Danta, C.C. SARS-CoV-2, Hypoxia, and Calcium Signaling: The Consequences and therapeutic options. *ACS Pharmacol. Trans. Sci.* **2021**, *4*, 400–402. [CrossRef]

102. Mori, Y.; Takahashi, N.; Kurokawa, T.; Kiyonaka, S. TRP channels in oxygen physiology: Distinctive functional properties and roles of TRPA1 in O₂ sensing. *Proc. Jpn. Acad.* **2017**, *93*, 464–482. [CrossRef] [PubMed]

103. El-Arif, G.; Khazaal, S.; Farhat, A.; Harb, J.; Annweiler, C.; Wu, Y.; Cao, Z.; Kovacic, H.; Khattar, Z.A.; Fajloun, Z.; et al. Angiotensin II Type I Receptor (AT1R): The gate towards COVID-19-associated diseases. *Molecules* **2022**, *27*, 2048. [CrossRef] [PubMed]

104. Attiq, A.; Yao, L.J.; Afzal, S.; Khan, M.A. The triumvirate of NF-κB, inflammation and cytokine storm in COVID-19. *Int. Immunopharmacol.* **2021**, *101*, 108255. [CrossRef] [PubMed]

105. Cron, R.Q.; Caricchio, R.; Chatham, W.W. Calming the cytokine storm in COVID-19. *Nat. Med.* **2021**, *27*, 1672–1678. [CrossRef]

106. Zanza, C.; Romenskaya, T.; Manetti, A.C.; Franceschi, F.; La Russa, R.; Bertozzi, G.; Maiese, A.; Savioli, G.; Volonnino, G.; Longhitano, Y. Cytokine storm in COVID-19: Immunopathogenesis and theory. *Medicina* **2022**, *58*, 144. [CrossRef]

107. Liu, F.; Li, L.; Xu, M.; Wu, J.; Luo, D.; Zhu, Y.; Li, B.; Song, X.; Zhou, X. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. *J. Clin. Virol.* **2020**, *127*, 104370. [CrossRef]

108. William, C.; Koehne, P.; Jürgensen, J.S.; Gräfe, M.; Wagner, K.D.; Bachmann, S.; Frei, U.; Eckardt, K.W. Tie2 receptor expression is stimulated by hypoxia and proinflammatory cytokines in human endothelial cells. *Circ. Res.* **2000**, *87*, 370–377. [CrossRef]

109. Melhorn, J.; Alamoudi, A.; Mentzer, A.J.; Fraser, E.; Fries, A.; Cassar, M.P.; Kwok, A.; Knight, J.C.; Raman, B.; Talbot, N.P.; et al. Persistence of inflammatory and vascular mediators five months after hospitalisation with COVID-19 infection. *Front. Med.* **2023**, *10*, 1056506. [CrossRef]

110. Eguchi, S.; Kawai, T.; Scalia, R.; Rizzo, V. Understanding angiotensin II type 1 receptor signaling in vascular pathophysiology. *Hypertension* **2018**, *71*, 804–810. [CrossRef]

111. Lam, S.Y.; Fung, M.-L.; Leung, P.S. Regulation of the angiotensin-converting enzyme activity by a time-course hypoxia in the carotid body. *J. Appl. Physiol.* **2004**, *96*, 809–813. [CrossRef]

112. Morrell, N.W.; A Higham, M.; Phillips, P.G.; Shakur, B.H.; Robinson, P.J.; Beddoes, R.J. Pilot study of losartan for pulmonary hypertension in chronic obstructive pulmonary disease. *Respir. Res.* **2005**, *6*, 88. [CrossRef]

113. Morrell, N.W.; Morris, K.G.; Stenmark, K.R. Role of angiotensin converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. *Am. J. Physiol.* **1995**, *269*, H1186–H1194. [CrossRef]

114. Koka, V.; Huang, X.R.; Chung, A.C.; Wang, W.; Truong, L.D.; Lan, H.Y. Angiotensin II Up-Regulates Angiotensin I Converting Enzyme (ACE), but Down-Regulates ACE2 via the AT1-ERK/p38 MAP Kinase Pathway. *Am. J. Pathol.* **2008**, *172*, 1174–1183. [CrossRef]

115. Zhang, R.; Wu, Y.; Zhao, M.; Liu, C.; Zhou, L.; Shen, S.; Liao, S.; Yang, K.; Li, Q.; Wan, H. Role of HIF-1 in the regulation ACE and ACE2 expression in hypoxic human pulmonary artery smooth muscle cells. *Am. J. Physiol. Lung Cell Mol. Physiol.* **2009**, *297*, L631–L640. [CrossRef]

116. Fazeli, G.; Stopper, H.; Schinzel, R.; Ni, C.-W.; Jo, H.; Schupp, N. Angiotensin II induces DNA damage via AT1 receptor and NADPH oxidase isoform Nox4. *Mutagenesis* **2012**, *27*, 673–681. [CrossRef]

117. Park, J.-M.; Do, V.Q.; Seo, Y.-S.; Kim, H.J.; Nam, J.H.; Yin, M.Z.; Kim, H.J.; Kim, S.J.; Griendling, K.K.; Lee, M.-Y. NADPH Oxidase 1 Mediates Acute Blood Pressure Response to Angiotensin II by Contributing to Calcium Influx in Vascular Smooth Muscle Cells. *Arterioscler. Thromb. Vasc. Biol.* **2022**, *42*, e117–e130. [CrossRef]

118. Richard, D.E.; Berra, E.; Gothié, E.; Pouysségur, J.R. p42/p44 Mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional Activity of HIF-1. *J. Biol. Chem.* **1999**, *274*, 32631–32637. [CrossRef]

119. McClendon, J.; Jansing, N.L.; Redente, E.F.; Gandjeva, A.; Ito, Y.; Colgan, S.P.; Ahmad, A.; Riches, D.W.; Chapman, H.A.; Mason, R.J.; et al. Hypoxia-inducible factor 1α signaling promotes repair of the alveolar epithelium after acute lung injury. *Am. J. Pathol.* **2017**, *187*, 1772–1786. [CrossRef]

120. Zhu, Q.; Wang, Z.; Xia, M.; Li, P.-L.; Van Tassell, B.W.; Abbate, A.; Dhaduk, R.; Li, N. Silencing of hypoxia-inducible factor-1α gene attenuated angiotensin II-induced renal injury in Sprague-Dawley rats. *Hypertension* **2011**, *58*, 657–664. [CrossRef]

121. Imperio, G.E.; Lye, P.; Mughis, H.; Hamada, H.; Bloise, E.; Lye, S.J.; Matthews, S.G. Hypoxia alters the expression of ACE2 and TMPRSS2 SARS-CoV-2 cell entry mediators in hCMEC/D3 brain endothelial cells. *Microvasc. Res.* **2021**, *138*, 104232. [CrossRef]

122. Zakheim, R.M.; Molteni, A.; Mattioli, L.; Park, M. Plasma angiotensin II levels in hypoxic and hypovolemic stress in unanesthetized rabbits. *J. Appl. Physiol.* **1976**, *41*, 462–465. [CrossRef] [PubMed]

123. Cao, Y. The impact of the hypoxia-VEGF-vascular permeability on COVID-19-infected patients. *Exploration* **2021**, *1*, 20210051. [CrossRef] [PubMed]

124. Afsar, B.; Kanbay, M.; Afsar, R.E. Hypoxia inducible factor-1 protects against COVID-19: A hypothesis. *Med. Hypothesis* **2020**, *143*, 109857. [CrossRef] [PubMed]

125. Foster, G.E.; Hanly, P.J.; Ahmed, S.B.; Beaudin, A.E.; Pialoux, V.; Poulin, M.J. Intermittent Hypoxia Increases Arterial Blood Pressure in Humans Through a Renin-Angiotensin System-Dependent Mechanism. *Hypertension* **2010**, *56*, 369–377. [CrossRef]

126. Takahashi, S.; Nakamura, Y.; Nishijima, T.; Sakurai, S.; Inoue, H. Essential roles of angiotensin II in vascular endothelial growth factor expression in sleep apnea syndrome. *Respir. Med.* **2005**, *99*, 1125–1131. [CrossRef]
127. Wright, J.M. Choosing a first-line drug in the management of elevated blood pressure: What is the evidence? **3**: Angiotensin-converting-enzyme inhibitors. *CMAJ* **2000**, *163*, 293-296.

128. Mentz, R.J.; Bakris, G.L.; Waeber, B.; McMurray, J.J.; Gheorghiade, M.; Ruilope, L.M.; Maggioni, A.P.; Swedberg, K.; Piña, I.L.; Fiuzat, M.; et al. The past, present and future of renin-angiotensin aldosterone system inhibition. *Int. J. Cardiol.* **2013**, *167*, 1677-1687. [CrossRef]

129. Schiffrin, E.L.; Flack, J.M.; Ito, S.; Muntner, P.; Webb, R.C. Hypertension and COVID-19. *Am. J. Hypertens.* **2020**, *33*, 373-374. [CrossRef]

130. Devaux, C.A. Are ACE inhibitors and ARBs more beneficial than harmful in the treatment of severe COVID-19 disease? *J. Cardiovasc. Med. Cardiol.* **2020**, *7*, 101-103. [CrossRef]

131. de Souza, G.A.P.; Osman, I.O.; Le Bideau, M.; Baudoin, J.-P.; Jaafar, R.; Devaux, C.; La Scola, B. Angiotensin II receptor blockers (ARBs antihypertensive agents) increase replication of SARS-CoV-2 in Vero E6 Cells. *Front. Cell. Infect. Microbiol.* **2021**, *11*, 639177. [CrossRef]

132. Shen, L.; Mo, H.; Cai, L.; Kong, T.; Zheng, W.; Ye, J.; Qi, J.; Xiao, Z. Losartan prevents sepsis-induced acute lung injury and decreases activation of nuclear factor kappaB and mitogen-activated protein kinases. *Shock* **2009**, *31*, 500-506. [CrossRef]

133. Meng, J.; Xiao, G.; Zhang, J.; He, X.; Ou, M.; Bi, J.; Yang, R.; Di, W.; Wang, Z.; Li, Z.; et al. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension. *Emerg. Microbes Infect.* **2020**, *9*, 757-760. [CrossRef]

134. Bean, D.M.; Kraljevic, Z.; Searle, T.; Bendayan, R.; Kevin, O.; Pickles, A.; Folarin, A.; Roguski, L.; Noor, K.; Shek, A.; et al. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID-19 infection in a multi-site UK acute hospital trust. *Eur. J. Heart Fail.* **2020**, *22*, 967-974. [CrossRef]

135. Zhang, P.; Zhu, L.; Cai, J.; Lei, F.; Qin, J.-J.; Xie, J.; Yuan, Y.; Loomba, R.; Liu, P.P.; Li, H.; et al. Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. *Circ. Res.* **2020**, *126*, 1671-1681. [CrossRef]

136. Abbasi, J. Choose ARBs Over ACE Inhibitors for First-line Hypertension Treatment, Large New Analysis Suggests. *JAMA*. **2021**, *326*, 1244-1245. [CrossRef]

137. Lopes, R.D.; Macedo, A.V.S.; de Barros, E.S.P.G.M.; Moll-Bernardes, R.J.; Dos Santos, T.M.; Mazza, L.; Feldman, A.; D'Andrea Saba Arruda, G.; de Albuquerque, D.C.; Camiletti, A.S.; et al. Continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19. A randomized clinical trial. *JAMA* **2021**, *325*, 254-264. [CrossRef]

138. Donoghue, M.; Hsieh, F.; Baronas, E.; Godbout, K.; Gosselin, M.; Stagliano, N.; Donovan, M.; Woolf, B.; Robison, K.; Jeyaseelan, R.; et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ. Res.* **2000**, *87*, E1-E9. [CrossRef]

139. Tipnis, S.R.; Hooper, N.M.; Hyde, R. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captoprilinsensitive carboxypeptidase. *J. Biol. Chem.* **2000**, *275*, 33238-33243. [CrossRef]

140. Descamps, G.; Verset, L.; Trelcat, A.; Hopkins, C.; Lechien, J.R.; Journe, F.; Saussez, S. ACE2 protein landscape in the head and neck region: The conundrum of SARS-CoV-2 infection. *Biology* **2020**, *9*, 235. [CrossRef]

141. Bourgonje, A.R.; Abdulle, A.E.; Timens, W.; Hillebrands, J.L.; Navis, G.J.; Gordijn, S.J.; Bolling, M.C.; Dijkstra, G.; Voors, A.A.; Osterhaus, A.D.; et al. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). *J. Pathol.* **2020**, *251*, 228-248. [CrossRef]

142. Henry, B.M.; Vikse, J.; Benoit, S.; Favaloro, E.J.; Lippi, G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. *Clin. Chim. Acta* **2020**, *507*, 167-173. [CrossRef] [PubMed]

143. Brown, N.J.; Vaughan, D.E. Prothrombotic effects of angiotensin. *Adv. Intern. Med.* **2000**, *45*, 419-429. [PubMed]

144. Larsson, P.T.; Schwieler, J.H.; Wallen, N.H. Platelet activation during angiotensin II infusion in healthy volunteers. *Blood Coag. Fibrinolysis* **2000**, *11*, 61-69. [CrossRef]

145. Fletcher-Sandersjöö, A.; Bellander, B.M. Is COVID-19 associated thrombosis caused by overactivation of the complement cascade? A literature review. *Thromb. Res.* **2020**, *194*, 36-41. [CrossRef]

146. Gando, S.; Wada, T. Thromboplasminflammation in COVID-19 Coagulopathy: Three Viewpoints for Diagnostic and Therapeutic Strategies. *Front. Immunol.* **2021**, *12*, 649122. [CrossRef]

147. Mogielnicki, A.; Kramkowski, K.; Hermanowicz, J.M.; Leszczynska, A.; Przyborowski, K.; Buczko, W. Angiotensin-(1-9) enhances stasisinduced venous thrombosis in the rat because of the impairment of fibrinolysis. *J. Renin Angiotensin Aldosterone Syst.* **2014**, *15*, 13-21. [CrossRef]

148. Zhang, S.; Liu, Y.; Wang, X.; Yang, L.; Li, H.; Wang, Y.; Liu, M.; Zhao, X.; Xie, Y.; Yang, Y.; et al. SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19. *J. Hematol. Oncol.* **2020**, *13*, 120. [CrossRef]

149. Kallet, R.H.; Branson, R.D.; Lipnick, M.S. Respiratory drive, dyspnea, and silent hypoxemia: A physiological review in the context of COVID-19. *Resp. Care* **2022**, *67*, 1343-1360. [CrossRef]

150. Carsana, L.; Sanzagni, A.; Nasr, A.; Rossi, R.S.; Pellegrinelli, A.; Zerbi, P.; Rech, R.; Colombo, R.; Antinori, S.; Corbellino, M.; et al. Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: A two-Centre descriptive study. *Lancet* **2020**, *300*, 1135-1140. [CrossRef]
151. Hofman, P.; Copin, M.C.; Tauziede-Espariat, A.; Adle-Biassette, H.; Fortarezza, F.; Passeron, T.; Salmon, I.; Calabrese, F. Histopathological features due to the SARS-CoV-2. *Ann. Pathol.* **2021**, *41*, 9–22. [CrossRef]

152. Zubieta-Calleja, G.R.; Zubieta-DeUrioste, N.; Montelongo, F.D.J.; Sanchez, M.G.R.; Campoverdi, A.F.; Rocco, P.R.M.; Battaglini, D.; Ball, L.; Pelosi, P. Morphological and functional findings in COVID-19 lung disease as compared to Pneumonia, ARDS, and High-Altitude Pulmonary Edema. *Respir. Physiol. Neurobiol.* **2023**, *309*, 104000. [CrossRef]

153. Goshua, G.; Pine, A.B.; Meizlish, M.L.; Chang, C.-H.; Zhang, H.; Bahel, P.; Baluha, A.; Bar, N.; Bona, R.D.; Burns, A.J.; et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. *Lancet Haematol.* **2020**, *7*, e575–e582. [CrossRef]

154. Gustafsson, L.; Leone, A.; Persson, M.; Wiklund, N.; Moncada, S. Endogenous Nitric Oxide is present in the exhaled air of rabbits, guinea pigs and humans. *Biochem. Biophys. Res. Commun.* **1991**, *181*, 852–857. [CrossRef]

155. Scherrer, U.; Vollenweider, L.; Delabays, A.; Savcic, M.; Eichenberger, U.; Kleger, G.-R.; Fikrle, A.; Ballmer, P.E.; Nicod, P.; Bärtsch, P. Inhaled nitric oxide for high-altitude pulmonary edema. *N. Engl. J. Med.* **1996**, *334*, 624–629. [CrossRef]

156. Brito-Azevedo, A.; Costa Pinto, E.; de Cata Preta Corrêa, G.A.; Bouskela, E. SARS-CoV-2 infection causes pulmonary shunt by vasodilatation. *J. Med. Virol.* **2021**, *93*, 573–575. [CrossRef]

157. Alamé, K.; Lemaitre, E.L.; Vuillaume, L.A.; Noizet, M.; Gottwalles, Y.; Chouihed, T.; Lavoignet, C.-E.; Bérard, L.; Molter, L.; Gennai, S.; et al. Silent hypoxemia in the emergency department: A retrospective cohort of two clinical phenotypes in critical COVID-19. *J. Clin. Med.* **2022**, *11*, 5034. [CrossRef]

158. Ssentongo, A.E.; Ssentongo, P.; Heilbrunn, E.S.; Lekoubou, A.; Du, P.; Liao, D.; Oh, J.S.; Chinchilli, V.M. Renin–angiotensin–aldosterone system inhibitors and the risk of mortality in patients with hypertension hospitalised for COVID-19: Systematic review and meta-analysis. *Open Heart* **2020**, *7*, e001353. [CrossRef]

159. Wing, P.A.C.; Keeley, T.P.; Zhuang, X.; Lee, J.Y.; Prange-Barczynska, M.; Tsukuda, S.; Morgan, S.B.; Harding, A.C.; Argles, I.L.; Kurlekar, S.; et al. Hypoxic and pharmacological activation of HIF inhibits SARS-CoV-2 infection of lung epithelial cells. *Cell Rep.* **2021**, *35*, 109020. [CrossRef]

160. Wing, P.A.C.; Prange-Barczynska, M.; Cross, A.; Crotta, S.; Rubio, C.O.; Cheng, X.; Harris, J.M.; Zhuang, X.; Johnson, R.L.; Ryan, K.A.; et al. Hypoxia inducible factors regulate infectious SARS-CoV-2, epithelial damage and respiratory symptoms in a hamster COVID-19 model. *PLoS Pathog.* **2022**, *18*, e1010807. [CrossRef]

161. Tian, M.; Liu, W.; Li, X.; Zhao, P.; Shereen, M.A.; Zhu, C.; Huang, S.; Liu, S.; Yu, X.; Yue, M.; et al. HIF-1α promotes SARS-CoV-2 infection and aggravates inflammatory responses to COVID-19. *Signal Transduct. Target. Therapy* **2021**, *6*, 308. [CrossRef]

162. Zalpoor, H.; Akbari, A.; Nabi-Afjadi, M.; Forghaniesfidvajani, R.; Tavakol, C.; Barzegar, Z.; Iravanpour, F.; Hosseini, M.; Mousavi, S.R.; Farrokhi, M.R. Hypoxia-inducible factor 1 alpha (HIF-1α) stimulated and P2X7 receptor activated by COVID-19, as a potential therapeutic target and risk factor for epilepsy. *Hum. Cell* **2022**, *35*, 1338–1345. [CrossRef] [PubMed]

163. Kotagiri, P.; Mescia, F.; Hanson, A.L.; Turner, L.; Bergamaschi, L.; Peñalver, A.; Richoz, N.; Moore, S.D.; Ortmann, B.M.; Dunmore, B.J.; et al. The impact of hypoxia on B cells in COVID-19. *eBioMedicine* **2022**, *77*, 103878. [CrossRef] [PubMed]

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.